Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1996 Apr 16;93(8):3357–3361. doi: 10.1073/pnas.93.8.3357

Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2.

H Molina 1, V M Holers 1, B Li 1, Y Fung 1, S Mariathasan 1, J Goellner 1, J Strauss-Schoenberger 1, R W Karr 1, D D Chaplin 1
PMCID: PMC39612  PMID: 8622941

Abstract

Complement receptor 1 (CR1, CD35) and complement receptor 2 (CR2, CD21) have been implicated as regulators of B-cell activation. We explored the role of these receptors in the development of humoral immunity by generating CR1- and CR2-deficient mice using gene-targeting techniques. These mice have normal basal levels of IgM and of IgG isotypes. B- and T-cell development are overtly normal. Nevertheless, B-cell responses to low and high doses of a T-cell-dependent antigen are impaired with decreased titers of antigen-specific IgM and IgG isotypes. This defect is not complete because there is still partial activation of B lymphocytes during the primary immune response, with generation of splenic germinal centers and a detectable, although reduced, secondary antibody response. These data suggest that certain T-dependent antigens manifest an absolute dependence on complement receptors for the initiation of a normally robust immune response.

Full text

PDF
3357

Images in this article

3358Fig. 1
on p.3358

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahearn J. M., Fearon D. T. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol. 1989;46:183–219. doi: 10.1016/s0065-2776(08)60654-9. [DOI] [PubMed] [Google Scholar]
  2. Aubry J. P., Pochon S., Graber P., Jansen K. U., Bonnefoy J. Y. CD21 is a ligand for CD23 and regulates IgE production. Nature. 1992 Aug 6;358(6386):505–507. doi: 10.1038/358505a0. [DOI] [PubMed] [Google Scholar]
  3. De Togni P., Goellner J., Ruddle N. H., Streeter P. R., Fick A., Mariathasan S., Smith S. C., Carlson R., Shornick L. P., Strauss-Schoenberger J. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science. 1994 Apr 29;264(5159):703–707. doi: 10.1126/science.8171322. [DOI] [PubMed] [Google Scholar]
  4. Engel P., Zhou L. J., Ord D. C., Sato S., Koller B., Tedder T. F. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995 Jul;3(1):39–50. doi: 10.1016/1074-7613(95)90157-4. [DOI] [PubMed] [Google Scholar]
  5. Fearon D. T. The CD19-CR2-TAPA-1 complex, CD45 and signaling by the antigen receptor of B lymphocytes. Curr Opin Immunol. 1993 Jun;5(3):341–348. doi: 10.1016/0952-7915(93)90051-s. [DOI] [PubMed] [Google Scholar]
  6. Frade R., Gauffre A., Hermann J., Barel M. EBV/C3d receptor (CR2) interacts by its intracytoplasmic carboxy-terminal domain and two distinct binding sites with the p53 anti-oncoprotein and the p68 calcium-binding protein. J Immunol. 1992 Nov 15;149(10):3232–3238. [PubMed] [Google Scholar]
  7. Gustavsson S., Kinoshita T., Heyman B. Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction. J Immunol. 1995 Jun 15;154(12):6524–6528. [PubMed] [Google Scholar]
  8. Hebell T., Ahearn J. M., Fearon D. T. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science. 1991 Oct 4;254(5028):102–105. doi: 10.1126/science.1718035. [DOI] [PubMed] [Google Scholar]
  9. Heyman B., Holmquist G., Borwell P., Heyman U. An enzyme-linked immunosorbent assay for measuring anti-sheep erythrocyte antibodies. J Immunol Methods. 1984 Mar 30;68(1-2):193–204. doi: 10.1016/0022-1759(84)90150-9. [DOI] [PubMed] [Google Scholar]
  10. Heyman B., Wiersma E. J., Kinoshita T. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J Exp Med. 1990 Aug 1;172(2):665–668. doi: 10.1084/jem.172.2.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hivroz C., Fischer E., Kazatchkine M. D., Grillot-Courvalin C. Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells. J Immunol. 1991 Mar 15;146(6):1766–1772. [PubMed] [Google Scholar]
  12. Holers V. M., Kinoshita T., Molina H. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol Today. 1992 Jun;13(6):231–236. doi: 10.1016/0167-5699(92)90160-9. [DOI] [PubMed] [Google Scholar]
  13. Hourcade D., Holers V. M., Atkinson J. P. The regulators of complement activation (RCA) gene cluster. Adv Immunol. 1989;45:381–416. doi: 10.1016/s0065-2776(08)60697-5. [DOI] [PubMed] [Google Scholar]
  14. Kinoshita T., Lavoie S., Nussenzweig V. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1). J Immunol. 1985 Apr;134(4):2564–2570. [PubMed] [Google Scholar]
  15. Kinoshita T., Takeda J., Hong K., Kozono H., Sakai H., Inoue K. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J Immunol. 1988 May 1;140(9):3066–3072. [PubMed] [Google Scholar]
  16. Kozono Y., Duke R. C., Schleicher M. S., Holers V. M. Co-ligation of mouse complement receptors 1 and 2 with surface IgM rescues splenic B cells and WEHI-231 cells from anti-surface IgM-induced apoptosis. Eur J Immunol. 1995 Apr;25(4):1013–1017. doi: 10.1002/eji.1830250423. [DOI] [PubMed] [Google Scholar]
  17. Kurtz C. B., O'Toole E., Christensen S. M., Weis J. H. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J Immunol. 1990 May 1;144(9):3581–3591. [PubMed] [Google Scholar]
  18. Laird P. W., Zijderveld A., Linders K., Rudnicki M. A., Jaenisch R., Berns A. Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 1991 Aug 11;19(15):4293–4293. doi: 10.1093/nar/19.15.4293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mansour S. L., Thomas K. R., Capecchi M. R. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature. 1988 Nov 24;336(6197):348–352. doi: 10.1038/336348a0. [DOI] [PubMed] [Google Scholar]
  20. Molina H., Brenner C., Jacobi S., Gorka J., Carel J. C., Kinoshita T., Holers V. M. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. J Biol Chem. 1991 Jul 5;266(19):12173–12179. [PubMed] [Google Scholar]
  21. Molina H., Kinoshita T., Inoue K., Carel J. C., Holers V. M. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol. 1990 Nov 1;145(9):2974–2983. [PubMed] [Google Scholar]
  22. Molina H., Wong W., Kinoshita T., Brenner C., Foley S., Holers V. M. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med. 1992 Jan 1;175(1):121–129. doi: 10.1084/jem.175.1.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rickert R. C., Rajewsky K., Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature. 1995 Jul 27;376(6538):352–355. doi: 10.1038/376352a0. [DOI] [PubMed] [Google Scholar]
  24. Tedder T. F., Zhou L. J., Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today. 1994 Sep;15(9):437–442. doi: 10.1016/0167-5699(94)90274-7. [DOI] [PubMed] [Google Scholar]
  25. Thyphronitis G., Kinoshita T., Inoue K., Schweinle J. E., Tsokos G. C., Metcalf E. S., Finkelman F. D., Balow J. E. Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo. J Immunol. 1991 Jul 1;147(1):224–230. [PubMed] [Google Scholar]
  26. Tuveson D. A., Ahearn J. M., Matsumoto A. K., Fearon D. T. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J Exp Med. 1991 May 1;173(5):1083–1089. doi: 10.1084/jem.173.5.1083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Weigle W. O., Goodman M. G., Morgan E. L., Hugli T. E. Regulation of immune response by components of the complement cascade and their activated fragments. Springer Semin Immunopathol. 1983;6(2-3):173–194. doi: 10.1007/BF00205872. [DOI] [PubMed] [Google Scholar]
  28. Wiersma E. J., Kinoshita T., Heyman B. Inhibition of immunological memory and T-independent humoral responses by monoclonal antibodies specific for murine complement receptors. Eur J Immunol. 1991 Oct;21(10):2501–2506. doi: 10.1002/eji.1830211029. [DOI] [PubMed] [Google Scholar]
  29. Wiersma E. J., Nose M., Heyman B. Evidence of IgG-mediated enhancement of the antibody response in vivo without complement activation via the classical pathway. Eur J Immunol. 1990 Dec;20(12):2585–2589. doi: 10.1002/eji.1830201209. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES